Immunohistochemical detection of “ex novo” HLA‐DR in tumor cells determines clinical outcome in laryngeal cancer patients

HLA ◽  
2021 ◽  
Author(s):  
Chiara Prampolini ◽  
Giovanni Almadori ◽  
Davide Bonvissuto ◽  
Marta Barba ◽  
Luca Giraldi ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Laryngeal Cancer ◽  
Immunohistochemical Detection ◽  
Hla Dr

scholarly journals Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Georg Lurje ◽  
Marc Schiesser ◽  
Andreas Claudius Hoffmann ◽  
Paul Magnus Schneider
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Disease Progression ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Response To Therapy ◽  
Clinical Implications ◽  
Gastrointestinal Malignancies ◽  
Progression Of Disease

Since their introduction more than 50 years by Engell, circulating tumor cells (CTCs) have been evaluated in cancer patients and their detection has been correlated with clinical outcome, in esophageal, gastric, and colorectal cancer. With the availability of refined technologies, the identification of CTCs from peripheral blood is emerging as a useful tool for the detection of malignancy, monitoring disease progression, and measuring response to therapy. However, increasing evidence suggests a variety of factors to be responsible for disease progression. The analysis of a single CTC marker is therefore unlikely to accurately predict progression of disease with sufficient resolution and reproducibility. Here we discuss the current concept of CTCs, summarize the available techniques for their detection and characterization, and aim to provide a comprehensive update on the clinical implications of CTCs in gastrointestinal (GI) malignancies.

Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients

2012 ◽  
Vol 65 (2) ◽  
pp. 263-273 ◽  
Author(s):  
Shu Zhao ◽  
Huike Yang ◽  
Minghui Zhang ◽  
Dekai Zhang ◽  
Yupeng Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Rt Pcr

scholarly journals Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients

2012 ◽  
Vol 14 (5) ◽  
Author(s):  
Antonia Patsialou ◽  
Yarong Wang ◽  
Juan Lin ◽  
Kathleen Whitney ◽  
Sumanta Goswami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Clinical Outcome ◽  
Gene Expression Profiling ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Expression Profiling ◽  
Breast Cancer Patients

scholarly journals Immunohistochemical Detection of Tumor Cells in the Bone Marrow of Breast Cancer Patients

1998 ◽  
Vol 28 (8) ◽  
pp. 480-485
Author(s):  
A. Okumura ◽  
Y. Tokuda ◽  
M. Tanaka ◽  
H. Makuuchi ◽  
T. Tajima
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Immunohistochemical Detection ◽  
Breast Cancer Patients

scholarly journals HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients

2006 ◽  
Vol 12 (6) ◽  
pp. 1715-1720 ◽  
Author(s):  
Pia Wülfing ◽  
Julia Borchard ◽  
Horst Buerger ◽  
Stefan Heidl ◽  
Kurt S. Zänker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Poor Clinical Outcome ◽  
Her2 Positive

Persistence of circulating tumour cells after treatment predicts clinical outcome in breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21080-21080
Author(s):  
M. Serrano ◽  
P. Sánchez-Rovira ◽  
M. Campos ◽  
F. Warleta ◽  
J. Ruiz-Mora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Regression Analysis ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Proportional Hazard ◽  
Breast Cancer Patients ◽  
Cox Proportional Hazard ◽  
Cox Proportional Hazard Regression

21080 Background: The hematogenous distant metastasis is the leading cause of cancer death. This process involves the passage through the blood and lymphatic circulation of circulating tumor cells (CTC) with metastatic properties. Thus, the early detection of such cells has important implication for cancer prognosis, monitoring of treatment and to predict clinical outcome. We present the results that showed that CTC are prognostic factor after chemotherapy independently of treatment. Methods: A total of 59 patients with breast cancer were enrolled in this study between April 2000 and December 2002. The median follow-up was 50 months. All patients received chemotherapy as first line treatment. Results of this work included CTC detection one month after of the end of chemotherapy. After informed consent, 10ml of heparinized peripheral blood was collected from patients. For enrichment of CTC we use the Carcinoma Cell Enrichment and Detection kit using MACS technology (Miltenyi Biotec). After enrichment of epithelial tumor cells immunomagnetic labeled with a multi- cytokeratin-specific antibody, the positive cells were detected by immunocytochemical staining with alkaline phosphatase substrate. Results: Analysis of CTC after chemotherapy: Circulating tumor cells were detected in 32 patients (54.23%). A mean number of cells were detected 3.7 (SD 13.9; range 1–105).The number of CTC was correlationed with progression free of disease (PFS) and overall survival (OS). In the univariate Cox proportional hazard regression analysis number cells were significantly associated with OS (p = 0.020) and PFS (p = 0.008). In the multivariate Cox proportional hazard regression analysis, number cells admit borderline statically significance with PFS (p = 0.052) and OS (p = 0.071). Conclusions: Our results suggest that the persistence of CTC after the treatment predicts clinical outcome and therefore the detection of CTC in breast cancer patients might allow monitoring of chemotherapy response. No significant financial relationships to disclose.

scholarly journals A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Eleni-Kyriaki Vetsika ◽  
Filippos Koinis ◽  
Marianthi Gioulbasani ◽  
Despoina Aggouraki ◽  
Anna Koutoulaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Suppressor Cells ◽  
Progression Free Survival ◽  
Myeloid Derived Suppressor Cells ◽  
Free Survival ◽  
Hla Dr ◽  
Nsclc Patients

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of cells with immunosuppressive properties and might confer to worse prognosis in cancer patients. The presence of phenotypically newly described subpopulations of MDSCs and their association with the clinical outcome were investigated in non-small cell lung cancer (NSCLC) patients. The percentages and correlation between MDSCs and distinct immune cells in the peripheral blood of 110 chemotherapy-naive patients before treatment and healthy controls were investigated using flow cytometry. Two monocytic [CD14+CD15−CD11b+CD33+HLA-DR−Lin−and CD14+CD15+CD11b+CD33+HLA-DR−Lin−] and a granulocytic [CD14−CD15+CD11b+CD33+HLA-DR−Lin−] subpopulations of MDSCs were identified, expressing inducible nitric oxide synthase, and reactive oxygen species, respectively. Increased percentages of both monocytic-MDSCs’ subpopulations were inversely correlated to dendritic/monocyte levels(P≤0.04), while granulocytic-MDSCs were inversely correlated to CD4+T cells(P=0.006). Increased percentages of monocytic-MDSCs were associated with worse response to treatment(P=0.02)and patients with normal levels of CD14+CD15+CD11b+CD33+HLA-DR−Lin−had longer overall survival and progression free-survival compared to those with high levels(P=0.008andP=0.005, resp.). Multivariate analysis revealed that the increased percentages of CD14+CD15+CD11b+CD33+HLA-DR−Lin−MDSCs were independently associated with decreased progression free-survival and overall survival. The data provide evidence that increased percentages of new monocytic-MDSCs’ subpopulations in advanced NSCLC patients are associated with an unfavourable clinical outcome.

Abstract 4175: Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients

2011 ◽  
Author(s):  
Sjoerd T. Ligthart ◽  
Frank A.W. Coumans ◽  
Gerhardt Attard ◽  
Johann S. de Bono ◽  
Leon W.M.M. Terstappen
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Automated Classification ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document